Data Insights

Lonigutamab ugodotin by Laboratoires Pierre Fabre for Squamous Non-Small Cell Lung Cancer: Likelihood of Approval

Lonigutamab ugodotin is under clinical development by Laboratoires Pierre Fabre and currently in Phase II for Squamous Non-Small Cell Lung...

Likelihood of Approval and Phase Transition Success Rate Model - Lonigutamab Ugodotin in Squamous Non-Small Cell Lung Cancer

Data Insights

Lonigutamab ugodotin by Laboratoires Pierre Fabre for Laryngeal Cancer: Likelihood of Approval

Lonigutamab ugodotin is under clinical development by Laboratoires Pierre Fabre and currently in Phase II for Laryngeal Cancer. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Lonigutamab Ugodotin in Laryngeal Cancer

Data Insights

Lonigutamab ugodotin by Laboratoires Pierre Fabre for Soft Tissue Sarcoma: Likelihood of Approval

Lonigutamab ugodotin is under clinical development by Laboratoires Pierre Fabre and currently in Phase II for Soft Tissue Sarcoma. According...

Likelihood of Approval and Phase Transition Success Rate Model - Lonigutamab Ugodotin in Soft Tissue Sarcoma

Data Insights

Lonigutamab ugodotin by Laboratoires Pierre Fabre for Breast Cancer: Likelihood of Approval

Lonigutamab ugodotin is under clinical development by Laboratoires Pierre Fabre and currently in Phase II for Breast Cancer. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Lonigutamab Ugodotin in Breast Cancer

Data Insights

Lonigutamab ugodotin by Laboratoires Pierre Fabre for Soft Tissue Sarcoma: Likelihood of Approval

Lonigutamab ugodotin is under clinical development by Laboratoires Pierre Fabre and currently in Phase II for Soft Tissue Sarcoma. According...

Likelihood of Approval and Phase Transition Success Rate Model - Lonigutamab Ugodotin in Soft Tissue Sarcoma

Data Insights

Tabelecleucel by Laboratoires Pierre Fabre for Post-Transplant Lymphoproliferative Disorder: Likelihood of Approval

Tabelecleucel is under clinical development by Laboratoires Pierre Fabre and currently in Pre-Registration for Post-Transplant Lymphoproliferative Disorder. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Tabelecleucel in Post-Transplant Lymphoproliferative Disorder

Data Insights

Tabelecleucel by Laboratoires Pierre Fabre for Solid Tumor: Likelihood of Approval

Tabelecleucel is under clinical development by Laboratoires Pierre Fabre and currently in Phase II for Solid Tumor. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Tabelecleucel in Solid Tumor

Data Insights

Tabelecleucel by Laboratoires Pierre Fabre for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma): Likelihood of Approval

Tabelecleucel is under clinical development by Laboratoires Pierre Fabre and currently in Phase II for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)....

Likelihood of Approval and Phase Transition Success Rate Model - Tabelecleucel in Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)

Data Insights

Tabelecleucel by Laboratoires Pierre Fabre for Non-Hodgkin Lymphoma: Likelihood of Approval

Tabelecleucel is under clinical development by Laboratoires Pierre Fabre and currently in Phase II for Non-Hodgkin Lymphoma. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Tabelecleucel in Non-Hodgkin Lymphoma